Cargando…

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

BACKGOUND: Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matching‐adjusted indirect comparison (MAIC) was conducted to demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Joshua, Lin, Peggy L., Garcia‐Horton, Viviana, Guyot, Patricia, Singh, Erin, Zhou, Zheng‐Yi, Sievert, Mark, Taiji, Riley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134287/
https://www.ncbi.nlm.nih.gov/pubmed/36726287
http://dx.doi.org/10.1002/cam4.5584
_version_ 1785031729379016704
author Richter, Joshua
Lin, Peggy L.
Garcia‐Horton, Viviana
Guyot, Patricia
Singh, Erin
Zhou, Zheng‐Yi
Sievert, Mark
Taiji, Riley
author_facet Richter, Joshua
Lin, Peggy L.
Garcia‐Horton, Viviana
Guyot, Patricia
Singh, Erin
Zhou, Zheng‐Yi
Sievert, Mark
Taiji, Riley
author_sort Richter, Joshua
collection PubMed
description BACKGOUND: Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matching‐adjusted indirect comparison (MAIC) was conducted to demonstrate efficacy and safety of isatuximab+carfilzomib+dexamethasone (Isa‐Kd) versus daratumumab + lenalidomide + dexamethasone (Dara‐Rd) in RRMM. METHODS: Patient‐level data from IKEMA trial (Isa‐Kd, n = 179) were matched to aggregate data from POLLUX (Dara‐Rd, n = 286). Hazard ratios (HR) and 95% confidence intervals (CI) for progression‐free survival (PFS) and overall survival (OS) were generated by weighted Cox proportional hazard models. Odds ratios (OR), 95% CI, and p‐value were calculated for ≥very good partial response (≥VGPR) and treatment‐emergent adverse events (TEAEs). RESULTS: After matching, no significant differences were observed between Isa‐Kd and Dara‐Rd in baseline characteristics except for patients with >3 prior lines (0.0% vs. 4.9%). Isa‐Kd showed significantly better PFS (HR [95% CI]: 0.46 [0.24–0.86]; p = 0.0155), statistically non‐significant improvement favoring Isa‐Kd in OS (0.47 [0.20–1.09]; 0.0798), and ≥VGPR (OR [95% CI]: 1.53 [0.89–2.64]; p = 0.1252) than Dara‐Rd. Odds of occurrence were significantly lower for some all‐grade and grade 3/4 TEAEs with Isa‐Kd than Dara‐Rd. CONCLUSION: These results support Isa‐Kd as an efficacious treatment for early relapse in non‐lenalidomide refractory patients.
format Online
Article
Text
id pubmed-10134287
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101342872023-04-28 Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma Richter, Joshua Lin, Peggy L. Garcia‐Horton, Viviana Guyot, Patricia Singh, Erin Zhou, Zheng‐Yi Sievert, Mark Taiji, Riley Cancer Med RESEARCH ARTICLES BACKGOUND: Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matching‐adjusted indirect comparison (MAIC) was conducted to demonstrate efficacy and safety of isatuximab+carfilzomib+dexamethasone (Isa‐Kd) versus daratumumab + lenalidomide + dexamethasone (Dara‐Rd) in RRMM. METHODS: Patient‐level data from IKEMA trial (Isa‐Kd, n = 179) were matched to aggregate data from POLLUX (Dara‐Rd, n = 286). Hazard ratios (HR) and 95% confidence intervals (CI) for progression‐free survival (PFS) and overall survival (OS) were generated by weighted Cox proportional hazard models. Odds ratios (OR), 95% CI, and p‐value were calculated for ≥very good partial response (≥VGPR) and treatment‐emergent adverse events (TEAEs). RESULTS: After matching, no significant differences were observed between Isa‐Kd and Dara‐Rd in baseline characteristics except for patients with >3 prior lines (0.0% vs. 4.9%). Isa‐Kd showed significantly better PFS (HR [95% CI]: 0.46 [0.24–0.86]; p = 0.0155), statistically non‐significant improvement favoring Isa‐Kd in OS (0.47 [0.20–1.09]; 0.0798), and ≥VGPR (OR [95% CI]: 1.53 [0.89–2.64]; p = 0.1252) than Dara‐Rd. Odds of occurrence were significantly lower for some all‐grade and grade 3/4 TEAEs with Isa‐Kd than Dara‐Rd. CONCLUSION: These results support Isa‐Kd as an efficacious treatment for early relapse in non‐lenalidomide refractory patients. John Wiley and Sons Inc. 2023-02-01 /pmc/articles/PMC10134287/ /pubmed/36726287 http://dx.doi.org/10.1002/cam4.5584 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Richter, Joshua
Lin, Peggy L.
Garcia‐Horton, Viviana
Guyot, Patricia
Singh, Erin
Zhou, Zheng‐Yi
Sievert, Mark
Taiji, Riley
Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
title Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
title_full Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
title_fullStr Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
title_full_unstemmed Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
title_short Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
title_sort matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134287/
https://www.ncbi.nlm.nih.gov/pubmed/36726287
http://dx.doi.org/10.1002/cam4.5584
work_keys_str_mv AT richterjoshua matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma
AT linpeggyl matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma
AT garciahortonviviana matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma
AT guyotpatricia matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma
AT singherin matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma
AT zhouzhengyi matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma
AT sievertmark matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma
AT taijiriley matchingadjustedindirectcomparisonofisatuximabpluscarfilzomibanddexamethasonewithdaratumumabpluslenalidomideanddexamethasoneinrelapsedmultiplemyeloma